Shots:
- BI has entered into a global collaboration & licensing agreement with AimedBio to develop a novel ADC for a broad range of cancers, expanding NBE Therapeutics’ portfolio (BI subsidiary)
- As per the deal, AimedBio will receive ~$991M, incl. an upfront, development & regulatory milestones, plus commercial milestones, as well as net sales-based royalties
- AimedBio’s ADC targets a protein highly expressed in diverse cancers but limited in normal tissue, potentially delivering precise cytotoxic activity to tumor cells & is expected to enter clinical development in 2026
Ref: Boehringer Ingelheim| Image: Boehringer Ingelheim & AimedBio | Press Release
Related News:- Boehringer Ingelheim and Click Therapeutics Report P-III (CONVOKE) Trial Data on CT-155 for Schizophrenia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
